A photo of David Hildeman.

Director, Immunology Graduate Program

Professor, UC Department of Pediatrics



Biography & Affiliation

Clinical Interests

T cells; autoimmunity; sex differences in immune responses; apoptosis

Research Interests

Molecular factors that control the decision between tolerance and immunity within T lymphocytes; staphylococcal enterotoxins, recombinant vaccinia viruses, lymphocytic choriomeningitis virus and MHC tetrameric reagents; antigen -specific T cell responses; tolerance centers on regulation of mechanisms that control the survival and death of activated T cells in vivo, namely Bcl-2 and its antagonist Bim; manipulation and regulation of antigen-specific T cell responses via novel vaccine strategies to either induce tolerance or enhance immunity; mechanisms underlying sex-based differences in T cell responses and how these differences relate to autoimmune disease.

Academic Affiliation

Professor, UC Department of Pediatrics


Center for Translational Fibrosis Research, Immunobiology


PhD: University of Wisconsin-Madison, Madison, Wisconsin, 1997.


Castro-Rojas CM, Godarova A, Hummel SA, Shields A, Tremblay S, Alloway RR, Jordan MB, Woodle* ES, Hildeman* DA. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-Refractory Renal Allograft Rejection. Transplantation. 2019. *co-corresponding authors.

Almanan M, Raynor J, Sholl A, Wang M, Chougnet C, Cardin RD*, Hildeman* DA. Tissue-specific control of latent CMV reactivation by regulatory T cells. PLOS Pathogens. 2017;13(8):e1006507. * these two authors contributed equally.

Li K-P, Fahnrich A, Roy E, Cuda CM, Grimes HL, Perlman H, Kalies K, Hildeman DA. Temporal expression of Bim limits the development of TCR+ double negative and CD8αα intestinal epithelial lymphocytes. Journal of Immunology. 2017;198(1):257-269. *this paper was featured as an “in this issue” highlight.

Ladle B*, Li K-P*, Phillips M, Pucsek A, Haile A, Powell JD, Jaffee EM, Hildeman D*, Gamper CJ*. Do novo DNA methylation by DNMT3a controls early effector CD8+ T cell fate decisions following activation. Proceedings of the National Academy of Sciences. 2016;113(38):10631-6. *These authors contributed equally.

Niss O, Sholl A, Bleesing JJ, Hildeman DA. Dysregulated expression of Bim in ALPS patients driven by IL-10/Jak/Stat3 signaling. Journal of Allergy and Clinical Immunology. 2015;135(3):762-70.

Kurtulus S, Sholl A, Toe J, Raynor J, Tripathi P, Li K-P, Pellegrini M, Hildeman DA. Bim controls IL-15 availability and limits engagement of multiple BH-3 only proteins. Cell Death & Differentiation. 2015;22(1):174-84.

Tripathi P, Mitchell TC, Finkelman F, Hildeman D. Contraction of CD4+ T cell responses is not controlled by limiting amounts of IL-7. J. Immunol Cutting Edge. 2007;178:4027-4031.

Wojciechowski S, Tripathi P, Bourdeau T, Acero L, Grimes HL, Katz J, Finkelman FD, Hildeman D. Bim/Bcl-2 balance is critical to maintain naïve and memory T cell homeostasis. J Exp Med. 2007;204(7):1665-1675.

Hildeman D, Zhu Y, Mitchell T, Bouillet P, Strasser A, Kappler J, Marrack P. Activated T cell death in vivo mediated by the pro-apoptotic Bcl-2 family member Bim. Immunity. 2002;16:759-767.

Hildeman D, Mitchell T, Teague TK, Henson P, Day BJ, Kappler J, Marrack P. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity. 1999;10:735-744.